| 1 |
non-small cell lung cancer
(48861 times)
|
Neoplasms
(25344 times)
|
OS (5712 times)
EGFR (5197 times)
PFS (3816 times)
|
1981 Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
|
| 2 |
non-SCLC
(59 times)
|
Neoplasms
(32 times)
|
SCLC (59 times)
LCNEC (3 times)
OS (3 times)
|
1986 Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors.
|
| 3 |
non-small cell LC
(13 times)
|
Neoplasms
(4 times)
|
LC (12 times)
COPD (2 times)
EMT (2 times)
|
2006 Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center.
|
| 4 |
non-small-cell bronchial carcinoma
(11 times)
|
General Surgery
(3 times)
|
PET (2 times)
ETM (1 time)
FDG (1 time)
|
1995 [Strategy for staging non-small cell bronchial carcinoma (NSCLC) with special reference to imaging procedures].
|
| 5 |
Non-Small Cell Lung Cancers
(6 times)
|
Neoplasms
(4 times)
|
ALK (2 times)
FISH (2 times)
IHC (2 times)
|
1995 Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer.
|
| 6 |
NSCLC group
(3 times)
|
Neoplasms
(2 times)
|
CEA (1 time)
DKK1 (1 time)
ELISA (1 time)
|
2012 [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].
|
| 7 |
early-stagenon-small-cell lung cancer
(2 times)
|
Neoplasms
(2 times)
|
AUCs (1 time)
CCRT (1 time)
CGA (1 time)
|
2018 Multidisciplinary treatment of lung cancer in older patients: A review.
|
| 8 |
non-small cancer
(2 times)
|
Allergy and Immunology
(1 time)
|
KLK6 (1 time)
PAR2 (1 time)
|
2014 [The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
|
| 9 |
non-small cell lung cancer lung cancer
(2 times)
|
Science
(1 time)
|
ICB (1 time)
IL-33 (1 time)
RT-qPCR (1 time)
|
2016 The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.
|
| 10 |
non-squamous cell lung cancer
(2 times)
|
Health Services
(1 time)
|
EGFR-TKIs (1 time)
KM (1 time)
OS (1 time)
|
2016 Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.
|
| 11 |
progression ofnon-small cell lung cancer
(2 times)
|
Medicine
(1 time)
|
circRNAs (1 time)
HBE (1 time)
|
2016 Inhibiting CREPT reduces the proliferation and migration of non-small cell lung cancer cells by down-regulating cell cycle related protein.
|
| 12 |
abbreviations:Non-small cell lung cancer
(1 time)
|
Bioengineering
(1 time)
|
circRNA (1 time)
MSP (1 time)
PTEN (1 time)
|
2022 Circular RNA hsa_circ_0077837 is upregulated in non-small cell lung cancer to downregulate phosphatase and tensin homolog through methylation.
|
| 13 |
adenocarcinoma ornon-small cell lung cancer
(1 time)
|
|
ALK (1 time)
EML4 (1 time)
PCMZL (1 time)
|
2022 Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma.
|
| 14 |
cancer-non-small-cell lung carcinoma
(1 time)
|
Pulmonary Medicine
(1 time)
|
---
|
2008 CT, positron emission tomography, and MRI in staging lung cancer.
|
| 15 |
inhibitor-naive patients with ALK+non-small cell lung cancer
(1 time)
|
Medicine
(1 time)
|
AEs (1 time)
ALK (1 time)
iORR (1 time)
|
2022 Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
|
| 16 |
lung squamous cell carcinoma
(1 time)
|
Neoplasms
(1 time)
|
RCC (1 time)
|
2016 Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
|
| 17 |
mediastinum foroligometastaticnon-small cell lung cancer
(1 time)
|
|
COVID-19 (1 time)
RRP (1 time)
|
2021 Rapid Development of Clinically Symptomatic Radiation Recall Pneumonitis Immediately Following COVID-19 Vaccination.
|
| 18 |
negatively correlated with the sensitivity to cisplatin
(1 time)
|
Neoplasms
(1 time)
|
BRCA1 (1 time)
ERCC1 (1 time)
|
2008 ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
|
| 19 |
node positive lung cancer
(1 time)
|
Thoracic Surgical Procedures
(1 time)
|
---
|
2009 Surgical resection and survival of patients with unsuspected single node positive lung cancer (NSCLC) invading the descending aorta.
|
| 20 |
Non Small Cancer Lung Cells
(1 time)
|
Cell Biology
(1 time)
|
---
|
2009 Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases.
|
| 21 |
non—small cell lung cancer
(1 time)
|
Cell Biology
(1 time)
|
IGF1R (1 time)
|
2015 MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
|
| 22 |
non-SCLC tumors
(1 time)
|
Neoplasms
(1 time)
|
ExPuSC (1 time)
NE (1 time)
SCLC (1 time)
|
1992 Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines.
|
| 23 |
non-small cell bronchial cancers
(1 time)
|
General Surgery
(1 time)
|
---
|
2002 [Neo-adjuvant chemotherapy of non-small cell bronchial cancers (NSCLC)].
|
| 24 |
non-small cell lung cancer, not otherwise specified
(1 time)
|
Pathology
(1 time)
|
---
|
2000 Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category.
|
| 25 |
non-small cell metastatic lung cancer
(1 time)
|
Neoplasms
(1 time)
|
OS (1 time)
PDAC (1 time)
|
2019 Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy.
|
| 26 |
non-small cell squamous cell carcinoma
(1 time)
|
|
---
|
2020 Synchronous Multiple Primary Cancers of the Lung: The Rare Association of Non-Small Cell Carcinoma With a Carcinoid Tumor.
|
| 27 |
non-small-cell bronchopulmonary carcinoma
(1 time)
|
Neoplasms
(1 time)
|
MDR1 (1 time)
|
1998 Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo.
|
| 28 |
non-small-cell locally advanced lung cancer
(1 time)
|
Neoplasms
(1 time)
|
CR (1 time)
VMAT (1 time)
|
2012 [Are there any dosimetric advantages in using VMAT for treatment of locally advanced non-small cell lung cancer?].
|
| 29 |
non-small-cell lung cancer therapy
(1 time)
|
Pharmaceutical Preparations
(1 time)
|
EGFR (1 time)
|
2014 Metabolite characterization of anti-cancer agent gefitinib in human hepatocytes.
|
| 30 |
non-small-cell lung cancer, NSCLC
(1 time)
|
Biochemistry
(1 time)
|
---
|
2011 The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
|
| 31 |
non-smoking lung cancer
(1 time)
|
Pulmonary Medicine
(1 time)
|
CI (1 time)
CR (1 time)
OS (1 time)
|
2006 A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer.
|
| 32 |
nonfermenting (SWI/SNF)Non-small cell lung cancer
(1 time)
|
Neoplasms
(1 time)
|
ARID (1 time)
ICIs (1 time)
KM (1 time)
|
2022 Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
|
| 33 |
NSC lung cancer
(1 time)
|
Chemistry, Clinical
(1 time)
|
EGFR (1 time)
NSC (1 time)
|
2018 Tissue and Blood Biomarkers in Lung Cancer: A Review.
|
| 34 |
NSCLC cancer
(1 time)
|
Therapeutics
(1 time)
|
NRG1 (1 time)
NRG2 (1 time)
|
2021 NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
|
| 35 |
NSCLC cohort
(1 time)
|
|
FDA (1 time)
TTD (1 time)
VHA (1 time)
|
2022 Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
|
| 36 |
NSCLC cohort; DCR
(1 time)
|
Immunotherapy
(1 time)
|
AEs (1 time)
DCR (1 time)
irRECIST (1 time)
|
2022 First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
|
| 37 |
NSCLC, LUAD and LUSC tissues significantly increased
(1 time)
|
Neoplasms
(1 time)
|
FC (1 time)
GEO (1 time)
HOXA3 (1 time)
|
2018 Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
|
| 38 |
NSCLC-like
(1 time)
|
|
SCLC (2 times)
LCNEC (1 time)
|
2022 Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.
|
| 39 |
NSCLC-VECs
(1 time)
|
Cell Biology
(1 time)
|
MAPK (1 time)
MMP (1 time)
PI3K (1 time)
|
2022 Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways.
|
| 40 |
NSCLC/AR
(1 time)
|
|
ADAR1 (1 time)
CX3CL1 (1 time)
|
2021 RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating CX3CR1-fractalkine expression.
|
| 41 |
numerous algerian patients with bronchopulmonary cancers cells
(1 time)
|
Biology
(1 time)
|
---
|
2019 [In silico study of a functional mutation associated with non-small cell lung cancer: G12D mutation of exon 2 in KRAS gene].
|
| 42 |
patients withnon-small cell lung cancer
(1 time)
|
Neoplasms
(1 time)
|
EVs (1 time)
ICIs (1 time)
|
2022 Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients withnon-small cell lung cancer.
|
| 43 |
pneumonectomy fornon-small cell lung cancer
(1 time)
|
General Surgery
(1 time)
|
GPS (1 time)
ICU (1 time)
|
2016 Glasgow Prognostic Score Class 2 Predicts Prolonged Intensive Care Unit Stay in Patients Undergoing Pneumonectomy.
|
| 44 |
predominantly sarcomas,non-small cell lung cancer
(1 time)
|
|
NTRK (1 time)
|
2022 The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib.
|
| 45 |
recombination', 'non-small cell lung cancer
(1 time)
|
Neoplasms
(1 time)
|
CI (1 time)
HJURP (1 time)
HR (1 time)
|
2022 Prognostic value of Holliday junction-recognizing protein and its correlation with immune infiltrates in lung adenocarcinoma.
|
A Search Service for Abbreviation / Long Form